The Cancer Research Society and Ovarian Cancer Canada are proud to jointly launch a competition to fund some of Canada’s most promising research projects focused on ovarian cancer. The competition will award up to 6 grants, each totaling $225,000 over a two-year period.

These will enable scientists to test new treatments, leading to new clinical trials, and ultimately improved outcomes for women with this disease.

OvCAN Patient Partners have important roles in a wide range of activities, from reviewing clinical trial funding applications to sharing their lived experience directly with ovarian cancer researchers and scientists.

Dr. Kirk McManus and Dr. Mark Nachtigal's collaborative research project was recently awarded two years’ joint funding from Ovarian Cancer Canada and the Cancer Research Society.

Four OvCAN-funded clinical trials happening across Canada will provide a wide range of new insights.

Allen Zhang receives 2020 Anita Unruh Prize

While advancing research and treatment options for women diagnosed or at risk of the disease is a critical priority, exploring and informing women about disease prevention is also important to us.

PARP inhibitors (PARPi) are a new family of drugs being used in the treatment of ovarian cancer. 

Ovarian Cancer Canada Welcomes Long-Sought Investments in Research Funding